Animal models reveal role for tau phosphorylation in human disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 10, 2010, Pages 860-871

  Götz, Jürgen ^a   Gladbach, Amadeus ^a   Pennanen, Luis ^b   van Eersel, Janet ^a   Schild, Andreas ^c   David, Della ^b   Ittner, Lars M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid; Drosophila; Frontotemporal dementia; Kinase; Mice; Nematode; Phosphatase; Phosphorylation; Tau; Transgenic

Indexed keywords

AMYLOID BETA PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL MODEL; ARTICLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; DISEASE MODEL; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; PHOSPHORYLATION; TAU PROTEINS;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 77956056008     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.09.008     Document Type: Article

References (187)

1. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
2. Goedert M., Jakes R., Spillantini M.G., Crowther R.A., Cohen P., Vanmechelen E., Probst A., Gotz J., Burki K. Tau protein in Alzheimer's disease. Biochem. Soc. Trans. 1995, 23:80-85.
3. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
4. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4051-4055.
5. Gotz J. Tau and transgenic animal models. Brain Res. Brain Res. Rev. 2001, 35:266-286.
6. Chen F., David D., Ferrari A., Gotz J. Posttranslational modifications of tau-role in human tauopathies and modeling in transgenic animals. Curr. Drug Targets 2004, 5:503-515.
7. Jicha G.A., Lane E., Vincent I., Otvos L., Hoffmann R., Davies P. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J. Neurochem. 1997, 69:2087-2095.
8. Andreadis A., Brown W.M., Kosik K.S. Structure and novel exons of the human tau gene. Biochemistry 1992, 31:10626-10633.
9. Goedert M., Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. Embo J. 1990, 9:4225-4230.
10. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Heutink P., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
11. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998, 43:815-825.
12. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7737-7741.
13. Baker M., Mackenzie I.R., Pickering-Brown S.M., Gass J., Rademakers R., Lindholm C., Snowden J., Adamson J., Sadovnick A.D., Rollinson S., Cannon A., Dwosh E., Neary D., Melquist S., Richardson A., Dickson D., Berger Z., Eriksen J., Robinson T., Zehr C., Dickey C.A., Crook R., McGowan E., Mann D., Boeve B., Feldman H., Hutton M. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442:916-919.
14. Cruts M., Gijselinck I., van der Zee J., Engelborghs S., Wils H., Pirici D., Rademakers R., Vandenberghe R., Dermaut B., Martin J.J., van Duijn C., Peeters K., Sciot R., Santens P., De Pooter T., Mattheijssens M., Van den Broeck M., Cuijt I., Vennekens K., De Deyn P.P., Kumar-Singh S., Van Broeckhoven C. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006, 442:920-924.
15. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
16. Cook C., Zhang Y.J., Xu Y.F., Dickson D.W., Petrucelli L. TDP-43 in neurodegenerative disorders. Expert Opin. Biol. Ther. 2008, 8:969-978.
17. Guevara J., Espinosa B., Zenteno E., Vazguez L., Luna J., Perry G., Mena R. Altered glycosylation pattern of proteins in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1998, 57:905-914.
18. Yao P.J., Coleman P.D. Reduction of O-linked N-acetylglucosamine-modified assembly protein-3 in Alzheimer's disease. J. Neurosci. 1998, 18:2399-2411.
19. Robertson L.A., Moya K.L., Breen K.C. The potential role of tau protein O-glycosylation in Alzheimer's disease. J. Alzheimers Dis. 2004, 6:489-495.
20. Liu F., Iqbal K., Grundke-Iqbal I., Hart G.W., Gong C.X. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10804-10809.
21. Mandelkow E.M., Thies E., Trinczek B., Biernat J., Mandelkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J. Cell Biol. 2004, 167:99-110.
22. Goedert M., Spillantini M.G., Jakes R., Crowther R.A., Vanmechelen E., Probst A., Gotz J., Burki K., Cohen P. Molecular dissection of the paired helical filament. Neurobiol. Aging 1995, 16:325-334.
23. Tanaka T., Iqbal K., Trenkner E., Liu D.J., Grundke-Iqbal I. Abnormally phosphorylated tau in SY5Y human neuroblastoma cells. FEBS Lett. 1995, 360:5-9.
24. Mandell J.W., Banker G.A. A spatial gradient of tau protein phosphorylation in nascent axons. J. Neurosci. 1996, 16:5727-5740.
25. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4913-4917.
26. Ihara Y., Nukina N., Miura R., Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem. (Tokyo) 1986, 99:1807-1810.
27. Hasegawa M., Jakes R., Crowther R.A., Lee V.M., Ihara Y., Goedert M. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett. 1996, 384:25-30.
28. Hoffmann R., Lee V.M., Leight S., Varga I., Otvos L. Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Biochemistry 1997, 36:8114-8124.
29. Bussiere T., Hof P.R., Mailliot C., Brown C.D., Caillet-Boudin M.L., Perl D.P., Buee L., Delacourte A. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol. (Berl.) 1999, 97:221-230.
30. Flament S., Delacourte A., Hemon B., Defossez A. [Direct demonstration of abnormal phosphorylation of Tau microtubular proteins in Alzheimer's disease]. C. R. Acad. Sci. 1989, III(308):77-82.
31. Hanger D.P., Brion J.P., Gallo J.M., Cairns N.J., Luthert P.J., Anderton B.H. Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem. J. 1991, 275(Pt. 1):99-104.
32. Goedert M., Spillantini M.G., Cairns N.J., Crowther R.A. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992, 8:159-168.
33. Greenberg S.G., Davies P., Schein J.D., Binder L.I. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 1992, 267:564-569.
34. Garver T.D., Harris K.A., Lehman R.A., Lee V.M., Trojanowski J.Q., Billingsley M.L. Tau phosphorylation in human, primate, and rat brain: evidence that a pool of tau is highly phosphorylated in vivo and is rapidly dephosphorylated in vitro. J. Neurochem. 1994, 63:2279-2287.
35. Ksiezak-Reding H., Binder L.I., Yen S.H. Alzheimer disease proteins (A68) share epitopes with tau but show distinct biochemical properties. J. Neurosci. Res. 1990, 25:420-430.
36. Drewes G., Mandelkow E.M., Baumann K., Goris J., Merlevede W., Mandelkow E. Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. FEBS Lett. 1993, 336:425-432.
37. Iqbal K., Zaidi T., Bancher C., Grundke-Iqbal I. Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett. 1994, 349:104-108.
38. Hasegawa M., Morishima-Kawashima M., Takio K., Suzuki M., Titani K., Ihara Y. Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J. Biol. Chem. 1992, 267:17047-17054.
39. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 1995, 270:823-829.
40. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Watanabe A., Titani K., Ihara Y. Hyperphosphorylation of tau in PHF. Neurobiol. Aging 1995, 16:365-371. discussion 371-380.
41. Hanger D.P., Betts J.C., Loviny T.L., Blackstock W.P., Anderton B.H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 1998, 71:2465-2476.
42. Friedhoff P., Mandelkow E.M. Tau protein. Guidebook to the cytoskeletal and motor proteins 1999, 230-236. Oxford University Press, Oxford. T. Kreis, R. Vale (Eds.).
43. Hanger D.P., Byers H.L., Wray S., Leung K.Y., Saxton M.J., Seereeram A., Reynolds C.H., Ward M.A., Anderton B.H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 2007, 282:23645-23654.
44. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. (Berl) 2002, 103:26-35.
45. Zheng-Fischhofer Q., Biernat J., Mandelkow E.M., Illenberger S., Godemann R., Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur. J. Biochem. 1998, 252:542-552.
46. Derkinderen P., Scales T.M., Hanger D.P., Leung K.Y., Byers H.L., Ward M.A., Lenz C., Price C., Bird I.N., Perera T., Kellie S., Williamson R., Noble W., Van Etten R.A., Leroy K., Brion J.P., Reynolds C.H., Anderton B.H. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J. Neurosci. 2005, 25:6584-6593.
47. Brandt R., Leger J., Lee G. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J. Cell Biol. 1995, 131:1327-1340.
48. Lee G., Newman S.T., Gard D.L., Band H., Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell. Sci. 1998, 111:3167-3177.
49. Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K., Fang S.M., Do L.H., Andreadis A., Van Hoesen G., Ksiezak-Reding H. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J. Neurosci. 2004, 24:2304-2312.
50. Bhaskar K., Yen S.H., Lee G. Disease-related modifications in tau affect the interaction between Fyn and Tau. J. Biol. Chem. 2005, 280:35119-35125.
51. Ittner L.M., Gotz J. Pronuclear injection for the generation of transgenic mice. Nat. Protoc. 2007, 2:1206-1215.
52. Gotz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9:532-544.
53. Shahani N., Subramaniam S., Wolf T., Tackenberg C., Brandt R. Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. J. Neurosci. 2006, 26:6103-6114.
54. Gotz J., Probst A., Spillantini M.G., Schafer T., Jakes R., Burki K., Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 1995, 14:1304-1313.
55. Brion J.P., Tremp G., Octave J.N. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease [see comments]. Am. J. Pathol. 1999, 154:255-270.
56. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., Lee V.M. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999, 24:751-762.
57. Spittaels K., Van den Haute C., Van Dorpe J., Bruynseels K., Vandezande K., Laenen I., Geerts H., Mercken M., Sciot R., Van Lommel A., Loos R., Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 1999, 155:2153-2165.
58. Probst A., Gotz J., Wiederhold K.H., Tolnay M., Mistl C., Jaton A.L., Hong M., Ishihara T., Lee V.M., Trojanowski J.Q., Jakes R., Crowther R.A., Spillantini M.G., Burki K., Goedert M. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. (Berl.) 2000, 99:469-481.
59. Ishihara T., Zhang B., Higuchi M., Yoshiyama Y., Trojanowski J.Q., Lee V.M. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am. J. Pathol. 2001, 158:555-562.
60. Gotz J., Nitsch R.M. Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice. Neuroreport 2001, 12:2007-2016.
61. Duff K., Knight H., Refolo L.M., Sanders S., Yu X., Picciano M., Malester B., Hutton M., Adamson J., Goedert M., Burki K., Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 2000, 7:87-98.
62. Tucker K.L., Meyer M., Barde Y.A. Neurotrophins are required for nerve growth during development. Nat. Neurosci. 2001, 4:29-37.
63. Kelleher I., Garwood C., Hanger D.P., Anderton B.H., Noble W. Kinase activities increase during the development of tauopathy in htau mice. J. Neurochem. 2007, 103:2256-2267.
64. Gotz J., Tolnay M., Barmettler R., Chen F., Probst A., Nitsch R.M. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur. J. Neurosci. 2001, 13:2131-2140.
65. Gotz J., Deters N., Doldissen A., Bokhari L., Ke Y., Wiesner A., Schonrock N., Ittner L.M. A decade of tau transgenic animal models and beyond. Brain Pathol. 2007, 17:91-103.
66. Hoerndli F.J., Toigo M., Schild A., Gotz J., Day P.J. Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal. Biochem. 2004, 335:30-41.
67. David D., Hoerndli F., Gotz J. Functional genomics meets neurodegenerative disorders. Part I. Transcriptomic and proteomic technology. Prog. Neurobiol. 2005, 76:153-168.
68. Hoerndli F., David D., Gotz J. Functional genomics meets neurodegenerative disorders. Part II. Application and data integration. Prog. Neurobiol. 2005, 76:169-188.
69. David D.C., Ittner L.M., Gehrig P., Nergenau D., Shepherd C., Halliday G., Gotz J. β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 2006, 6:6566-6577.
70. Sowell R.A., Owen J.B., Butterfield D.A. Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res. Rev. 2009, 8:1-17.
71. Pennanen L., Welzl H., D'Adamo P., Nitsch R.M., Gotz J. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol. Dis. 2004, 15:500-509.
72. Pennanen L., Wolfer D.P., Nitsch R.M., Gotz J. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav. 2006, 5:369-379.
73. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., Atzori C., Migheli A., Crowther R.A., Ghetti B., Spillantini M.G., Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 2002, 22:9340-9351.
74. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Murphy P.M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000, 25:402-405.
75. Gotz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 2001, 276:529-534.
76. Deters N., Ittner L.M., Gotz J. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur. J. Neurosci. 2008, 28:137-147.
77. Iqbal K., Alonso A.C., Gong C.X., Khatoon S., Pei J.J., Wang J.Z., Grundke-Iqbal I. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J. Neural Transm., Suppl. 1998, 53:169-180.
78. Delobel P., Lavenir I., Fraser G., Ingram E., Holzer M., Ghetti B., Spillantini M.G., Crowther R.A., Goedert M. Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am. J. Pathol. 2008, 172:123-131.
79. Berger Z., Roder H., Hanna A., Carlson A., Rangachari V., Yue M., Wszolek Z., Ashe K., Knight J., Dickson D., Andorfer C., Rosenberry T.L., Lewis J., Hutton M., Janus C. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 2007, 27:3650-3662.
80. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
81. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., Guimaraes A., Yue M., Lewis J., Carlson G., Hutton M., Ashe K.H. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci. 2005, 25:10637-10647.
82. Ittner L.M., Fath T., Ke Y.D., Bi M., van Eersel J., Li K.M., Gunning P., Gotz J. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15997-16002.
83. Neumann M., Schulz-Schaeffer W., Crowther R.A., Smith M.J., Spillantini M.G., Goedert M., Kretzschmar H.A. Pick's disease associated with the novel Tau gene mutation K369I. Ann. Neurol. 2001, 50:503-513.
84. van Eersel J., Bi M., Ke Y.D., Hodges J.R., Xuereb J.H., Gregory G.C., Halliday G.M., Gotz J., Kril J.J., Ittner L.M. Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm 2009, 116:1243-1251.
85. Ittner L.M., Ke Y.D., Gotz J. Phosphorylated tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 2009, 284:20909-20916.
86. Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., Jucker M., Goedert M., Tolnay M. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
87. Gotz J., Streffer J.R., David D., Schild A., Hoerndli F., Pennanen L., Kurosinski P., Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol. Psychiatry 2004, 9:664-683.
88. Kurosinski P., Gotz J. Glial cells under physiologic and pathological conditions. Arch. Neurol. 2002, 59:1524-1528.
89. Hanger D.P., Hughes K., Woodgett J.R., Brion J.P., Anderton B.H. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 1992, 147:58-62.
90. Mandelkow E.M., Drewes G., Biernat J., Gustke N., Van Lint J., Vandenheede J.R., Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 1992, 314:315-321.
91. Baumann K., Mandelkow E.M., Biernat J., Piwnica-Worms H., Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 1993, 336:417-424.
92. Hyman B.T., Elvhage T.E., Reiter J. Extracellular signal regulated kinases. Localization of protein and mRNA in the human hippocampal formation in Alzheimer's disease. Am. J. Pathol. 1994, 144:565-572.
93. Trinczek B., Biernat J., Baumann K., Mandelkow E.M., Mandelkow E. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol. Biol. Cell 1995, 6:1887-1902.
94. Reynolds C.H., Utton M.A., Gibb G.M., Yates A., Anderton B.H. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. J. Neurochem. 1997, 68:1736-1744.
95. Reynolds C.H., Nebreda A.R., Gibb G.M., Utton M.A., Anderton B.H. Reactivating kinase/p38 phosphorylates tau protein in vitro. J. Neurochem. 1997, 69:191-198.
96. Guimera J., Casas C., Estivill X., Pritchard M. Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 1999, 57:407-418.
97. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribe E., Dalfo E., Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 2005, 2:3-18.
98. Pei J.J., An W.L., Zhou X.W., Nishimura T., Norberg J., Benedikz E., Gotz J., Winblad B. P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett. 2006, 580:107-114.
99. Sato S., Cerny R.L., Buescher J.L., Ikezu T. Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. J. Neurochem. 2006, 98:1573-1584.
100. Li T., Paudel H.K. Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 2006, 45:3125-3133.
101. Li T., Hawkes C., Qureshi H.Y., Kar S., Paudel H.K. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 2006, 45:3134-3145.
102. Spittaels K., Van Den Haute C., Van Dorpe J., Geerts H., Mercken M., Bruynseels K., Lasrado R., Vandezande K., Laenen I., Boon T., Van Lint J., Vandenheede J., Moechars D., Loos R., Van Leuven F. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 2000, 275:41340-41349.
103. Engel T., Lucas J.J., Gomez-Ramos P., Moran M.A., Avila J., Hernandez F. Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol. Aging 2005, 97:1259-1268.
104. Engel T., Hernandez F., Avila J., Lucas J.J. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 2006, 26:5083-5090.
105. Gomez-Sintes R., Hernandez F., Bortolozzi A., Artigas F., Avila J., Zaratin P., Gotteland J.P., Lucas J.J. Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J. 2007, 26:2743-2754.
106. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., Gaynor K., LaFrancois J., Wang L., Kondo T., Davies P., Burns M., Veeranna, Nixon R., Dickson D., Matsuoka Y., Ahlijanian M., Lau L.F., Duff K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38:555-565.
107. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 2006, 281:25457-25465.
108. Wen Y., Planel E., Herman M., Figueroa H.Y., Wang L., Liu L., Lau L.F., Yu W.H., Duff K.E. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 2008, 28:2624-2632.
109. Cruz J.C., Tseng H.C., Goldman J.A., Shih H., Tsai L.H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
110. Muyllaert D., Terwel D., Kremer A., Sennvik K., Borghgraef P., Devijver H., Dewachter I., Van Leuven F. Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration. Am. J. Pathol. 2008, 172:470-485.
111. Sato S., Xu J., Okuyama S., Martinez L.B., Walsh S.M., Jacobsen M.T., Swan R.J., Schlautman J.D., Ciborowski P., Ikezu T. Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J. Neurosci. 2008, 28:14511-14521.
112. Zigman W.B., Lott I.T. Alzheimer's disease in Down syndrome: neurobiology and risk. Ment. Retard. Dev. Disabil. Res. Rev. 2007, 13:237-246.
113. Martinez de Lagran M., Altafaj X., Gallego X., Marti E., Estivill X., Sahun I., Fillat C., Dierssen M. Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. Neurobiol. Dis. 2004, 15:132-142.
114. Altafaj X., Ortiz-Abalia J., Fernandez M., Potier M.C., Laffaire J., Andreu N., Dierssen M., Gonzalez-Garcia C., Cena V., Marti E., Fillat C. Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiol. Dis. 2008, 32:377-384.
115. Ahn K.J., Jeong H.K., Choi H.S., Ryoo S.R., Kim Y.J., Goo J.S., Choi S.Y., Han J.S., Ha I., Song W.J. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 2006, 22:463-472.
116. Arque G., Fotaki V., Fernandez D., Martinez de Lagran M., Arbones M.L., Dierssen M. Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A). PLoS ONE 2008, 3:e2575.
117. Ryoo S.R., Jeong H.K., Radnaabazar C., Yoo J.J., Cho H.J., Lee H.W., Kim I.S., Cheon Y.H., Ahn Y.S., Chung S.H., Song W.J. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem. 2007, 282:34850-34857.
118. Shi J., Zhang T., Zhou C., Chohan M.O., Gu X., Wegiel J., Zhou J., Hwang Y.W., Iqbal K., Grundke-Iqbal I., Gong C.X., Liu F. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J. Biol. Chem. 2008, 283:28660-28669.
119. Goedert M., Jakes R., Qi Z., Wang J.H., Cohen P. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J. Neurochem. 1995, 65:2804-2807.
120. Sontag E., Nunbhakdi-Craig V., Lee G., Bloom G.S., Mumby M.C. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 1996, 17:1201-1207.
121. Sontag E., Nunbhakdi-Craig V., Lee G., Brandt R., Kamibayashi C., Kuret J., White C.L., Mumby M.C., Bloom G.S. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J. Biol. Chem. 1999, 274:25490-25498.
122. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 2005, 22:1942-1950.
123. Janssens V., Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 2001, 353:417-439.
124. Xie H., Clarke S. Protein phosphatase 2A is reversibly modified by methyl esterification at its C-terminal leucine residue in bovine brain. J. Biol. Chem. 1994, 269:1981-1984.
125. Bryant J.C., Westphal R.S., Wadzinski B.E. Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory Balpha subunit. Biochem. J. 1999, 339(Pt. 2):241-246.
126. Xu Y., Chen Y., Zhang P., Jeffrey P.D., Shi Y. Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Mol. Cell 2008, 31:873-885.
127. Arendt T., Holzer M., Fruth R., Bruckner M.K., Gartner U. Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 1995, 69:691-698.
128. Planel E., Yasutake K., Fujita S.C., Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J. Biol. Chem. 2001, 276:34298-34306.
129. Pei J.J., Gong C.X., An W.L., Winblad B., Cowburn R.F., Grundke-Iqbal I., Iqbal K. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am. J. Pathol. 2003, 163:845-858.
130. Gong C.X., Singh T.J., Grundke-Iqbal I., Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem. 1993, 61:921-927.
131. Chen C.M., Hou Y.T., Liu J.Y., Wu Y.R., Lin C.H., Fung H.C., Hsu W.C., Hsu Y., Lee S.H., Hsieh-Li H.M., Su M.T., Chen S.T., Lane H.Y., Lee-Chen G.J. PPP2R2B CAG repeat length in the Han Chinese in Taiwan: association analyses in neurological and psychiatric disorders and potential functional implications. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:124-129.
132. Gotz J., Schild A. Transgenic and knockout models of PP2A. Methods Enzymol. 2003, 366:390-403.
133. Gotz J., Probst A., Ehler E., Hemmings B., Kues W. Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Calpha. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12370-12375.
134. Gotz J., Kues W. The role of protein phosphatase 2A catalytic subunit Calpha in embryogenesis: evidence from sequence analysis and localization studies. Biol. Chem. 1999, 380:1117-1120.
135. Gotz J., Probst A., Mistl C., Nitsch R.M., Ehler E. Distinct role of protein phosphatase 2A subunit calpha in the regulation of E-cadherin and beta-catenin during development. Mech. Dev. 2000, 93:83-93.
136. Schmidt K., Kins S., Schild A., Nitsch R.M., Hemmings B.A., Gotz J. Diversity, developmental regulation and distribution of murine PR55/B subunits of protein phosphatase 2A. Eur. J. Neurosci. 2002, 16:2039-2048.
137. Martens E., Stevens S., Janssens J., Gotz J., Goris J., van Hoof C. Genomic organisation, chromosomal localisation, tissue distribution and developmental regulation of the PR61/B' regulatory subunits of protein phosphatase 2A in mice. J. Mol. Biol. 2004, 336:971-986.
138. Schild A., Schmidt K., Lim Y.A., Ke Y., Ittner L.M., Hemmings B.A., Gotz J. Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation. Int. J. Dev. Neurosci. 2006, 24:437-443.
139. Kins S., Crameri A., Evans D.R., Hemmings B.A., Nitsch R.M., Gotz J. Reduced PP2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem. 2001, 276:38193-38200.
140. Kins S., Kurosinski P., Nitsch R.M., Gotz J. Activation of the ERK and JNK signaling pathways caused by neuron specific inhibition of PP2A in transgenic mice. Am. J. Pathol. 2003, 163:833-843.
141. Schild A., Ittner L.M., Gotz J. Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice. Biochem. Biophys. Res. Commun. 2006, 343:1171-1178.
142. Schild A., Isenmann S., Tanimoto N., Tonagel F., Seeliger M.W., Ittner L.M., Kretz A., Ogris E., Gotz J. Impaired development of the Harderian gland in mutant protein phosphatase 2A transgenic mice. Mech. Dev. 2006, 123:362-371.
143. Deters N., Ittner L.M., Gotz J. Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem. Biophys. Res. Commun. 2009, 379:400-405.
144. Nunbhakdi-Craig V., Schuechner S., Sontag J.M., Montgomery L., Pallas D.C., Juno C., Mudrak I., Ogris E., Sontag E. Expression of protein phosphatase 2A mutants and silencing of the regulatory B alpha subunit induce a selective loss of acetylated and detyrosinated microtubules. J. Neurochem. 2007, 101:959-971.
145. Liu R., Zhou X.W., Tanila H., Bjorkdahl C., Wang J.Z., Guan Z.Z., Cao Y., Gustafsson J.A., Winblad B., Pei J.J. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J. Cell. Mol. Med. 2008, 12:241-257.
146. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
147. Meyer E.P., Ulmann-Schuler A., Staufenbiel M., Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3587-3592.
148. Karlnoski R.A., Rosenthal A., Kobayashi D., Pons J., Alamed J., Mercer M., Li Q., Gordon M.N., Gottschall P.E., Morgan D. Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J. Neurosci. 2009, 29:4964-4971.
149. Noda-Saita K., Terai K., Iwai A., Tsukamoto M., Shitaka Y., Kawabata S., Okada M., Yamaguchi T. Exclusive association and simultaneous appearance of congophilic plaques and AT8-positive dystrophic neurites in Tg2576 mice suggest a mechanism of senile plaque formation and progression of neuritic dystrophy in Alzheimer's disease. Acta Neuropathol. 2004, 108:435-442.
150. Melov S., Coskun P., Patel M., Tuinstra R., Cottrell B., Jun A.S., Zastawny T.H., Dizdaroglu M., Goodman S.I., Huang T.T., Miziorko H., Epstein C.J., Wallace D.C. Mitochondrial disease in superoxide dismutase 2 mutant mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:846-851.
151. Melov S., Adlard P.A., Morten K., Johnson F., Golden T.R., Hinerfeld D., Schilling B., Mavros C., Masters C.L., Volitakis I., Li Q.X., Laughton K., Hubbard A., Cherny R.A., Gibson B., Bush A.I. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE 2007, 2:e536.
152. Lewis J., Dickson D.W., Lin W.-L., Chisholm L., Corral A., Jones G., Yen S.-H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 2001, 293:1487-1491.
153. Gotz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
154. Ferrari A., Hoerndli F., Baechi T., Nitsch R.M., Gotz J. Beta-amyloid induces PHF-like tau filaments in tissue culture. J. Biol. Chem. 2003, 278:40162-40168.
155. Gotz J., Schild A., Hoerndli F., Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int. J. Dev. Neurosci. 2004, 22:453-465.
156. Pennanen L., Gotz J. Different tau epitopes define Abeta(42)-mediated tau insolubility. Biochem. Biophys. Res. Commun. 2005, 337:1097-1101.
157. David D.C., Hauptmann S., Scherping I., Schuessel K., Keil U., Rizzu P., Ravid R., Dröse S., Brandt U., Müller W.E., Eckert E., Gotz J. Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 2005, 280:23802-23814.
158. Eckert A., Hauptmann S., Scherping I., Meinhardt J., Rhein V., Drose S., Brandt U., Fandrich M., Muller W.E., Gotz J. Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial function in P301L tau transgenic mice. J. Mol. Med. 2008, 86:1255-1267.
159. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles. Intracellular abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
160. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24:1063-1070.
161. Bolmont T., Clavaguera F., Meyer-Luehmann M., Herzig M.C., Radde R., Staufenbiel M., Lewis J., Hutton M., Tolnay M., Jucker M. Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am. J. Pathol. 2007, 171:2012-2020.
162. Wittmann C.W., Wszolek M.F., Shulman J.M., Salvaterra P.M., Lewis J., Hutton M., Feany M.B. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001, 293:711-714.
163. Jackson G.R., Wiedau-Pazos M., Sang T.-K., Wagle N., Brown C.A., Massachi S., Geschwind D.H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002, 34:509-519.
164. Steinhilb M.L., Dias-Santagata D., Fulga T.A., Felch D.L., Feany M.B. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol. Biol. Cell 2007, 18:5060-5068.
165. Nishimura I., Yang Y., Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 2004, 116:671-682.
166. Chau K.W., Chan W.Y., Shaw P.C., Chan H.Y. Biochemical investigation of Tau protein phosphorylation status and its solubility properties in Drosophila. Biochem. Biophys. Res. Commun. 2006, 346:150-159.
167. Morcos M., Hutter H. The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease. J. Alzheimers Dis. 2009, 16:897-908.
168. Green R.A., Audhya A., Pozniakovsky A., Dammermann A., Pemble H., Monen J., Portier N., Hyman A., Desai A., Oegema K. Expression and imaging of fluorescent proteins in the C. elegans gonad and early embryo. Methods Cell Biol. 2008, 85:179-218.
169. Kraemer B.C., Zhang B., Leverenz J.B., Thomas J.H., Trojanowski J.Q., Schellenberg G.D. From the Cover: Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9980-9985.
170. Brandt R., Gergou A., Wacker I., Fath T., Hutter H. A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiol. Aging 2009, 30:22-33.
171. Hernandez F., Lim F., Lucas J.J., Perez-Martin C., Moreno F., Avila J. Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. Mini Rev. Med. Chem. 2002, 2:51-58.
172. Li G., Faibushevich A., Turunen B.J., Yoon S.O., Georg G., Michaelis M.L., Dobrowsky R.T. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J. Neurochem. 2003, 84:347-362.
173. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
174. Bussiere T., Hof P.R., Mailliot C., Brown C.D., Caillet-Boudin M.L., Perl D.P., Buee L., Delacourte A. Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol. (Berl.) 1999, 97:221-230.
175. Schneider A., Biernat J., von Bergen M., Mandelkow E., Mandelkow E.M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999, 38:3549-3558.
176. Wang Y.P., Biernat J., Pickhardt M., Mandelkow E., Mandelkow E.M. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10252-10257.
177. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
178. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
179. Gong C.X., Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 2008, 15:2321-2328.
180. Le Corre S., Klafki H.W., Plesnila N., Hubinger G., Obermeier A., Sahagun H., Monse B., Seneci P., Lewis J., Eriksen J., Zehr C., Yue M., McGowan E., Dickson D.W., Hutton M., Roder H.M. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9673-9678.
181. Caccamo A., Oddo S., Tran L.X., LaFerla F.M. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 2007, 170:1669-1675.
182. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:6990-6995.
183. Paquet D., Bhat R., Sydow A., Mandelkow E.M., Berg S., Hellberg S., Falting J., Distel M., Koster R.W., Schmid B., Haass C. A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J. Clin. Invest. 2009, 119:1382-1395.
184. Berger Z., Ravikumar B., Menzies F.M., Oroz L.G., Underwood B.R., Pangalos M.N., Schmitt I., Wullner U., Evert B.O., O'Kane C.J., Rubinsztein D.C. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 2006, 15:433-442.
185. Noda T., Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J. Biol. Chem. 1998, 273:3963-3966.
186. Zhang B., Maiti A., Shively S., Lakhani F., McDonald-Jones G., Bruce J., Lee E.B., Xie S.X., Joyce S., Li C., Toleikis P.M., Lee V.M., Trojanowski J.Q. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:227-231.
187. J. Gotz, N. Schonrock, B. Vissel, L.M. Ittner, Alzheimer's disease selective vulnerability and modelling in transgenic mice, J. Alzheimers Dis. (2009), Jul 7 [Electronic publication ahead of print].